Aronne 2025 — SURMOUNT-5 Tirzepatide vs Semaglutide Obesity Head-to-Head

New England Journal of Medicine·May 1, 2025

Louis J. Aronne, SURMOUNT-5 Investigators

Summary

SURMOUNT-5 reported greater reductions in body weight and waist circumference with tirzepatide compared with semaglutide at week 72.

Study Details

Study Design

Randomized open-label head-to-head phase 3 trial

Indication

Obesity or overweight with weight-related comorbidity

Intervention

Once-weekly tirzepatide vs once-weekly semaglutide

Species

Human

Risk of Bias Assessment

Open-label; sponsor-funded